


<b>Form PTO-1449</b> <b>(REV. 8-83)</b>		<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>		<b>Atty. Docket:</b> 2004117-0008 <b>(NEMC 197-DIV)</b>		<b>In re Application No.</b> 10/828,623	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT</b>  <i>(Use several sheets if necessary)</i>				<b>Applicant:</b> Carr <i>et al.</i>			
				<b>Filing Date:</b> April 21, 2004		<b>Group:</b> 1653	
<b>U. S. PATENT DOCUMENTS</b>							
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass		
BL	✓ 6,063,758	Lappi <i>et al.</i>	05/16/00				
BL	✓ 6,310,072	Smith <i>et al.</i>	10/30/01				
<b>U. S. PATENT APPLICATIONS</b>							
	Document No.	Applicant	Filing Date				
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner's Initials	Document No.	Country	Publication Date	Translation			
				Yes	No		
Examiner's Initials	<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)						
	✓ Cavagnero <i>et al.</i> , <i>Life Sci.</i> , 49(7):498-503, 1991.						
	✓ Watson <i>et al.</i> , <i>Eur. J. Pharmacol.</i> , 87(1):77-84, 1983.						
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>				
			9.20.06				
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

✓ Cited by the Examiner in parent case USSN 09/428,692 (US Patent No.: 6,759,520).

<b>Form PTO-1449</b> <b>(REV. 8-83)</b>  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  <i>(Use several sheets if necessary)</i>	<b>Atty. Docket:</b> 2004117-0008 (NEMC 197-DIV)	<b>In re Application No.</b> TBA
	<b>Applicant:</b> Carr <i>et al.</i>	
	<b>Filing Date:</b> April 21, 2004	<b>Group:</b> TBA

**U. S. PATENT DOCUMENTS**

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
BL	✓ 5,891,842	Kream	04/06/99		

**U. S. PATENT APPLICATIONS**

	Document No.	Applicant	Filing Date		

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Document No.	Country	Publication Date	Translation	
				Yes	No

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
BL	✓ Carr et al., "Neural Blockade in Clinical Anesthesia and Management of Pain", Third ed., pp. 915-983, 1998.
	✓ Foran et al., "Inhibition of Morphine Tolerance Development by a Substance P-Opioid Peptide chimera", <i>J. Pharmacol. Exp. Ther.</i> , 295(3): 1142-1148, 2000.
	✓ Foran et al., "A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic", <i>Proc. Natl. Acad. Sci.</i> , 97: 7621-7626, 2000.
	✓ Foran et al., "Chimeric peptide for the treatment of acute and chronic pain", <i>Anesthesiology</i> (Hagerstown), Vol. 91, No. 3A, 1999, p. A944 XP000996135 Annual Meeting of the American Society of Anesthesiologists; Dallas, Texas, USA; October 9-13, 1999 ISSN: 0003-3022.

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
2004117-0008  
(NEMC 197-DIV)

In re Application No.  
TBA

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant: Carr *et al.*

Filing Date:  
April 21, 2004

Group: TBA

BL

✓ Foran S., "Characterization of Novel Chimeric Analgesic Peptides", Ph.D. Dissertation, Tufts University, Sackler School of Graduate Biomedical Sciences, September 2000.

✓ Hyden et al., *Eur. J. Pharmacol.*, 86:95-98, 1983.

✓ Hyden et al., *J. Pharmacol. Exp. Ther.*, 226:398-404, 1983.

✓ Kream et al., *Proc. Nat'l. Acad. Sci. USA*, 90:3564-3568, 1993.

✓ Langel et al., "Design of chimeric peptide ligands to galanin receptors and substance P receptors", *International Journal of peptide and protein research*, DK, Munksgaard, Copenhagen, 39(6): 516-522, 1992.

✓ Lei et al., "Opioid and neurokinin activities of substance P fragments and their analogs", *Eur. J. Pharmacol.*, 193(2):209-215, 1991.

✓ Lipkowski et al., "Neuropeptides: Peptide and Nonpeptide Analogs", Gutte ed., Academic Press pp 287-320, 1995.

✓ Lipkowski et al., "An approach to the self regulatory mechanism of substance P actions: II. Biological activity of new synthetic peptide analogs related both to enkephalin and substance P", *Life Sciences*, 33(Sup. I): 141-144, 1983.

✓ Lipkowski et al., "Opioid Peptide Analogues: Reconsideration as a Potentially New Generation of Analgesics", *Polish J. Chem.*, 68: 907-912, 1994.

✓ Lipkowski et al., "Peptides as receptor selectivity modulators of opiate pharmacophores", *J. Med. Chem.*, 29: 1222-1225, 1986.

✓ Lipkowski et al., "Benzomorphan alkaloids, natural peptidomimetics of opioid peptide pharmacophores", *Lett. Peptide Res.*, 2: 177-181, 1995.

✓ Lipkowski et al., "Biological activities of a peptide containing both casomorphin-like and substance P antagonist structural characteristics", in *Casomorphins and related peptides. Recent developments*, V. Brantl, H. Teschemacher, eds, VCH, Weinheim, pp. 113-118, 1994.

✓ Maszczyńska et al., "Dual functional interactions of Substance P and opioids in nociceptive transmission: Review and Reconciliation", *Analgesia*, 3:259-268, 1998.

✓ Maszczyńska et al., "Alternative forms of interaction of substance P and opioids in nociceptive transmission", *Letters in Peptide Science*, 5: 395-398, 1998.

✓ Misterek et al., "Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide biphalin", *Life Sciences*, 54(14): 939-944, 1994.

✓ Patent Abstracts of Japan, Vol. 1999, No. 8, 30 June 1999 & JP 11060598 A (ASASHI

Form PTO-1449  
(REV. 8-83)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket:  
2004117-0008  
(NEMC 197-DIV)

In re Application No.  
TBA

**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant: Carr *et al.*

Filing Date:  
April 21, 2004

Group: TBA

GLASS CO LTD), 2 March 1999 abstract, page 3, Formula 1(A).

✓ Schiller et al., *J. Med. Chem.*, 36:3182-3187, 1993.

✓ Silbert et al., "Analgesic activity of a novel bivalent opioid peptide compared to morphine via different routes of administration", *Agents and Action*, 33:382-387, 1991.

✓ Silbert et al., *Prog. Clin. Biol.*, 328:485-488, 1990.

✓ Sizheng et al., "Opioid and neurokinin activities of substance P fragments and their analogs", *Eur. J. Pharmacology*, 193: 209-215, 1991.

✓ Ward et al., *J. Med. Chem.*, 33:1848-1851, 1990.

✓ Zadina et al., *Life Sci.*, 55:461-466, 1994.

EXAMINER

DATE CONSIDERED 9-20-06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.